



Attorney's Docket No.: 01997-289001  
Client's Reference No.: 9025

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Aleksey G. Kazantsev *et al.* Art Unit : 1653  
Serial No. : 09/933,638 Examiner : Anand U. Desai  
Filed : August 20, 2001  
Title : INHIBITION OF PROTEIN-PROTEIN INTERACTION

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

DECLARATION OF DR. LESLIE THOMPSON UNDER 37 C.F.R. 1.131

I, Leslie M. Thompson, am a citizen of the United States of America, and I reside at 19 McClintock Court, Irvine, California. I hereby declare as follows.

1. I am an inventor of the subject matter now claimed in the patent application referenced above (herein, "the application").

2. Prior to March 16, 2000, I worked with others at the University of California – Irvine to develop an animal model that could be used to screen and identify therapeutic agents useful in ameliorating diseases, such as Huntington's Disease, which are associated with undesirable protein-protein interactions within affected cells. Some of the work performed to generate that animal model was described in an article entitled, "Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in *Drosophila*", which was published in *Human Molecular Genetics*, 9(1):13-25, 2000. The manuscript was received by the journal on August 23, 1999.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

November 29, 2005  
Date of Deposit

Leslie M. Thompson  
Signature

Leslie M. Thompson  
Typed or Printed Name of Person Signing Certificate

BEST AVAILABLE COPY

Applicant : Aleksey G. Kazantsev *et al.*  
Serial No. : 09/933,638  
Filed : August 20, 2001  
Page : 2 of 2

Attorney's Docket No.: 01997-289001  
Client's Reference No.: 9025

3. Prior to March 16, 2000, I worked with others at the University of California – Irvine to test therapeutic agents in the animal model described above. As described in Example 2 of the application, co-expression of (1) an expanded polyglutamine repeat peptide and (2) an agent designed to inhibit aggregation of the repeat peptide, reduced lethality in *Drosophila*. The same therapeutic agent rescued degenerating neurons in the *Drosophila* eye. One of the therapeutic agents tested in Example 2 is referred to as H3/H4 because it includes a domain that consists of a polypeptide comprising two of the alpha-helical regions (H3 and H4) of the tata-binding protein (see Figure 1). The alpha-helical regions constitute the “third domain” as they separate a first domain that binds a first protein and a second domain that binds a second protein.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true. I further declare that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

11/23/05  
Date

Leslie M. Thompson  
Leslie M. Thompson

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

21210548.doc

BEST AVAILABLE COPY